# Promimic

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/promimic).

## Overview

Promimic is a Swedish medical technology company that develops and licenses nanotechnology-based surface modifications for implants. Its technology is used by implant manufacturers to improve how bone, soft tissue, and other biological structures integrate with the implant surface, with applications in orthopedics, dental implants, and other implant categories.

## Products & services

• Implant surface modification technologies
• Nano surface coatings for orthopedic implants
• Dental implant surface solutions
• Processing services via U.S. subsidiary NPI
• Licensing and royalty-based technology agreements
• New biomaterial and infection-prevention concepts

- **Licensing and royalties** (55%) — Technology licenses and royalty streams tied to customer implant sales.
- **Implant processing services** (30%) — Processing of customer implants through the U.S. subsidiary NPI.
- **Development and customer projects** (10%) — Collaborative development work and commercialization projects with customers.
- **Other surface-related offerings** (5%) — Additional implant surface and biomaterial solutions under development.

- Implant surface modification technologies
- Nano surface coatings for orthopedic implants
- Dental implant surface solutions
- Processing services via U.S. subsidiary NPI
- Licensing and royalty-based technology agreements
- New biomaterial and infection-prevention concepts

## Customers

Promimic sells primarily to medical device companies that manufacture implantable products and need validated surface technologies for their own regulatory and commercial programs. The customer base includes international medtech groups and implant makers in orthopedics and dental applications, where clinical performance and regulatory acceptance are central buying criteria.

- **Orthopedic implant manufacturers** (primary) — Buy surface technologies for joint, spine, trauma, and other orthopedic implants to improve clinical outcomes and differentiation.
- **Dental implant manufacturers** (primary) — Use Promimic's surface solutions for dental implants where faster and more reliable integration matters.
- **International medtech partners** (primary) — License the technology and collaborate on development, validation, and commercialization.
- **Customers using U.S. processing services** (secondary) — Buy implant processing through NPI instead of waiting for downstream royalty monetization.
- **New application developers** (emerging) — Explore patientspecific implants, soft-tissue integration, and biomaterial applications.

- Orthopedic implant manufacturers seeking better osseointegration
- Dental implant companies needing surface technology differentiation
- Medtech firms that license technology for their own implant lines
- Customers buying processing services through the U.S. subsidiary
- Partners pursuing clinical validation and regulatory approval

## Geography

Promimic is headquartered in Mölndal, Sweden, with operations centered around GoCo Health Innovation City. Commercially, the company has its largest market in the United States, while Brazil and Europe are also important markets; reported segment operations also include Estonia, Latvia, Lithuania, Germany, and Italy.

- **Estonia** (74.5%)
- **Latvia** (0.3%)
- **Lithuania** (11.8%)
- **Germany** (11.4%)
- **Italy** (2%)

- Headquartered in Mölndal, Västra Götaland, Sweden
- Operations based at GoCo Health Innovation City
- United States is the largest commercial market
- Brazil and Europe are also important markets
- Reported segment operations include Estonia, Latvia, Lithuania, Germany, and Italy

## Strategy

Promimic's strategy centers on expanding adoption of its implant surface technology through customer partnerships, clinical validation, and new license agreements. The company is also building commercial presence in the United States and broadening its offering into new implant surfaces, biomaterials, and infection-prevention applications.

- **U.S. commercial expansion** (medium-term) — The U.S. is the largest market and the main growth platform for orthopedic implants.
- **Customer partnership development** (short-term) — Longer-term royalties and adoption depend on customer integration and repeat collaborations.
- **Innovation and new applications** (medium-term) — New surface technologies can open additional implant categories and improve differentiation.
- **Broaden customer base** (short-term) — More customers reduce concentration and support scaling of the licensing model.

- Expand in the U.S. orthopedic implant market
- Add new customer agreements each year
- Deepen partnerships with existing medtech customers
- Increase clinical validation through strategic collaborations
- Launch new implant surface and biomaterial offerings

## Risks

Promimic's business depends on successful commercialization by a relatively small number of medtech customers, so delays in customer launches or regulatory approvals can directly affect future revenue. The company also faces foreign exchange exposure, especially USD, and execution risk from scaling U.S. operations while maintaining quality and regulatory compliance.

- **Dependence on large customers** [high] — A limited number of implant partners can materially affect revenue timing and scale.
- **Regulatory approval risk** [high] — Customer products must pass FDA/EMA and other regulatory reviews before commercialization.
- **USD foreign exchange exposure** [medium] — Most revenue is in USD while much of the cost base is in SEK.
- **Commercial execution in the U.S.** [medium] — Scaling sales, production, and support in the U.S. requires resources and coordination.
- **Commercialization uncertainty** [medium] — Adoption of new implant surface technologies can take time and depends on clinical proof.

- Customer concentration can delay or reduce royalty and license income
- FDA and EMA approvals are needed for customer implant launches
- USD exposure is significant because revenues are mainly in USD
- U.S. expansion requires management time, staffing, and process buildout
- Early-stage commercialization creates demand and adoption uncertainty

## Accounting

Promimic's reporting includes judgment-heavy areas around revenue timing, especially as the business combines royalties, license fees, and implant processing services. The company also uses hedge accounting for USD net flows, and its balance sheet includes intangible assets, development-related investments, and other estimates that can affect reported earnings and asset values.

- **Revenue recognition across royalties, licenses, and processing** — Can shift quarterly revenue and comparability
- **Foreign exchange hedging** — Affects finance income/cost and volatility
- **Intangible assets and development-related estimates** — Can materially affect amortization and impairment charges
- **Impairment testing** — Could lead to non-cash write-downs
- **Lease and PPE accounting** — Affects operating expense pattern and asset base

- Revenue mixes royalties, license fees, and processing income
- Timing of customer launches affects when revenue is recognized
- USD hedging affects reported finance results and cash flow
- Intangible assets and development costs require judgment
- Impairment testing matters for acquired or capitalized assets
- Lease and equipment accounting affect operating asset values

---

*Last updated: 2026-08-11T04:04:55.356125+00:00*